Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.83 |
| ▸ | CA12 | O43570 | 2/20 | 0.81 |
| ▸ | CA9 | Q16790 | 2/20 | 0.81 |
| ▸ | CA2 | P00918 | 7/20 | 0.81 |
| ▸ | CA1 | P00915 | 6/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.81 |
| ▸ | PDE5A | O76074 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | GLA | P06280 | 1/20 | 0.81 |
| ▸ | GAA | P10253 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | CDC42 | P60953 | 1/20 | 0.81 |
| ▸ | ATM | Q13315 | 1/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.81 |
| ▸ | ACHE | P22303 | 2/20 | 0.77 |
| ▸ | MMP2 | P08253 | 2/20 | 0.74 |
| ▸ | MMP9 | P14780 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18827569 | 0.95 | PTGS2 (0.92) | L3MBTL1PTGS2CA12CA9CA2 | |
| SCHEMBL12494043 | 0.89 | L3MBTL1 (1.00) | L3MBTL1PTGS2CA12CA9CA2 | |
| SCHEMBL15197341 | 0.89 | CA1 (1.00) | L3MBTL1PTGS2CA12CA9CA2 | |
| SCHEMBL18826390 | 0.87 | CA12 (0.80) | L3MBTL1PTGS2CA12CA9CA2 | |
| SCHEMBL15197348 | 0.86 | PTGS2 (0.77) | L3MBTL1PTGS2CA12CA9CA2 | |
| SCHEMBL15197343 | 0.86 | PTGS2 (0.77) | L3MBTL1PTGS2CA12CA9CA2 | |
| SCHEMBL18826388 | 0.86 | CA1 (0.91) | L3MBTL1PTGS2CA12CA9CA2 | |
| SCHEMBL15197347 | 0.86 | CA1 (1.00) | L3MBTL1PTGS2CA12CA9CA2 | |
| SCHEMBL18826382 | 0.84 | L3MBTL1 (0.84) | L3MBTL1PTGS2CA12CA9CA2 | |
| SCHEMBL18827566 | 0.84 | PTGS2 (0.89) | L3MBTL1PTGS2CA12CA9CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9259415-B2 | Efficacy in treating bacterial infections | BALL STATE INNOVATION CORPORATION (US) | 2016-02-16 | — | — | US | disclosed |
| US-9259415-B2 | Efficacy in treating bacterial infections | BALL STATE INNOVATION CORPORATION (US) | 2016-02-16 | — | — | US | disclosed |
| US-20130217744-A1 | EFFICACY IN TREATING BACTERIAL INFECTIONS | BALL STATE UNIVERSITY | 2013-08-22 | — | — | US | disclosed |
| US-20130217744-A1 | EFFICACY IN TREATING BACTERIAL INFECTIONS | BALL STATE UNIVERSITY | 2013-08-22 | — | — | US | disclosed |
| US-20070149591-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | STEPHENSON DIANE T | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149591-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | PTGS2, PTGS1, PTGES2 | L3MBTL1 3169/4885PTGS2 1/4885CA12 1857/4885 |
| US-20130217744-A1 | EFFICACY IN TREATING BACTERIAL INFECTIONS | CDC42, RAC1, CDC42BPG | L3MBTL1 1907/4885PTGS2 1588/4885CA12 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.